PharmaTher (PHRM.C)

PharmaTher (PHRM.C) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….